IRIS Institutional Research Information System - OPENBS Open Archive UniBS

Malagola, Michele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.898
AS - Asia 10.701
EU - Europa 8.567
SA - Sud America 2.504
AF - Africa 217
Continente sconosciuto - Info sul continente non disponibili 21
OC - Oceania 17
Totale 39.925
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.590
SG - Singapore 3.746
CN - Cina 3.370
UA - Ucraina 2.354
BR - Brasile 2.093
HK - Hong Kong 1.397
DE - Germania 1.346
IT - Italia 1.093
PL - Polonia 862
VN - Vietnam 765
FI - Finlandia 681
TR - Turchia 467
GB - Regno Unito 462
RU - Federazione Russa 459
IE - Irlanda 389
IN - India 296
SE - Svezia 295
FR - Francia 233
AR - Argentina 153
BD - Bangladesh 147
CA - Canada 136
MX - Messico 110
ZA - Sudafrica 92
IQ - Iraq 86
EC - Ecuador 70
CZ - Repubblica Ceca 64
NL - Olanda 64
ID - Indonesia 63
ES - Italia 58
CO - Colombia 52
JP - Giappone 51
AT - Austria 50
BE - Belgio 45
SA - Arabia Saudita 45
UZ - Uzbekistan 41
VE - Venezuela 41
PY - Paraguay 36
PK - Pakistan 33
MA - Marocco 25
JO - Giordania 23
KE - Kenya 22
AE - Emirati Arabi Uniti 21
IL - Israele 21
EG - Egitto 20
EU - Europa 20
CL - Cile 16
LT - Lituania 16
UY - Uruguay 16
AU - Australia 15
DK - Danimarca 15
JM - Giamaica 15
PE - Perù 15
IR - Iran 14
MU - Mauritius 14
AZ - Azerbaigian 12
OM - Oman 12
TH - Thailandia 12
DZ - Algeria 11
ET - Etiopia 11
TN - Tunisia 11
KZ - Kazakistan 10
MY - Malesia 10
PT - Portogallo 10
BG - Bulgaria 9
BO - Bolivia 9
DO - Repubblica Dominicana 9
NP - Nepal 9
GR - Grecia 8
HN - Honduras 8
PA - Panama 8
CR - Costa Rica 7
KR - Corea 7
AL - Albania 6
BA - Bosnia-Erzegovina 6
KG - Kirghizistan 6
PS - Palestinian Territory 6
AM - Armenia 5
LK - Sri Lanka 5
LV - Lettonia 5
RS - Serbia 5
SN - Senegal 5
CH - Svizzera 4
EE - Estonia 4
HU - Ungheria 4
LB - Libano 4
PH - Filippine 4
RO - Romania 4
SK - Slovacchia (Repubblica Slovacca) 4
BB - Barbados 3
CU - Cuba 3
HR - Croazia 3
KW - Kuwait 3
NI - Nicaragua 3
NO - Norvegia 3
TT - Trinidad e Tobago 3
AO - Angola 2
CI - Costa d'Avorio 2
GE - Georgia 2
GY - Guiana 2
LA - Repubblica Popolare Democratica del Laos 2
Totale 39.904
Salva come PNG Salva come JPEG
Città #
Woodbridge 2.001
Singapore 1.715
Jacksonville 1.615
Fairfield 1.565
Hong Kong 1.393
Houston 1.338
Ashburn 1.303
Ann Arbor 1.125
Warsaw 846
Princeton 736
Cambridge 734
Wilmington 730
Beijing 642
Seattle 632
Chandler 629
Nanjing 538
New York 471
Dublin 384
The Dalles 363
Los Angeles 351
Istanbul 349
Helsinki 289
Munich 271
Ho Chi Minh City 254
Des Moines 253
Nanchang 231
Brescia 227
Dallas 216
São Paulo 192
Hanoi 160
Buffalo 154
Moscow 148
Changsha 144
Redondo Beach 143
Jinan 129
Tianjin 123
Milan 122
Shenyang 121
Hebei 118
Shanghai 115
Dearborn 110
San Diego 107
San Francisco 101
Turku 89
Boardman 88
Chicago 86
Jiaxing 85
Hangzhou 72
Kunming 66
London 65
Kocaeli 64
Brooklyn 63
Santa Clara 63
Nuremberg 57
Ningbo 55
Rio de Janeiro 55
Verona 55
Brasília 51
Guangzhou 51
Brno 50
Regensburg 50
Johannesburg 49
Zhengzhou 49
Denver 47
Brussels 45
Belo Horizonte 44
Toronto 44
Curitiba 43
Tokyo 43
Pune 42
Rome 40
Mexico City 39
Boston 37
Orem 37
Atlanta 36
Tashkent 36
Lanzhou 35
Phoenix 34
Stockholm 34
Biên Hòa 33
Montreal 32
Chennai 31
Da Nang 30
Taizhou 30
Poplar 29
Baghdad 28
Haikou 26
Norwalk 26
Orange 26
Porto Alegre 26
Frankfurt am Main 25
Grafing 25
Manchester 24
Guayaquil 23
Salvador 23
Vienna 23
Charlotte 22
Dong Ket 22
Fortaleza 22
Ribeirão Preto 22
Totale 25.635
Salva come PNG Salva come JPEG
Nome #
Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis 300
Mesenchymal stromal cells (MSCs) induce ex vivo proliferation and erythroid commitment of cord blood haematopoietic stem cells (CB-CD34+ cells) 294
BACTERIAL BLOOD STREAM INFECTIONS NEGATIVELY IMPACT ON OUTCOME OF PATIENTS TREATED WITH ALLOGENEIC STEM CELL TRANSPLANTATION: 6 YEARS SINGLE-CENTRE EXPERIENCE 278
Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients 271
Circulating endothelial cell count: a reliable marker of endothelial damage in patients undergoing hematopoietic stem cell transplantation 260
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. 225
Zebrafish disease models in hematology: Highlights on biological and translational impact 218
Bloodstream infections in haematological cancer patients colonized by multidrug-resistant bacteria 193
A specific Toll-like receptor profile on T lymphocytes and values of monocytes correlate with bacterial, fungal, and cytomegalovirus infections in the early period of allogeneic stem cell transplantation 185
Feasibility of tumor‑derived exosome enrichment in the onco‑hematology leukemic model of chronic myeloid leukemia 185
Targeting HRASV12G Expression to the Zebrafish Early Hemogenic Progenitors Induces a Myeloproliferative Disorder by Repressing the Notch Pathway. 177
EXPRESSION OF TOLL-LIKE RECEPTORS ON PERIPHERAL BLOOD CELLS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: ONGOING RESULTS OF A PROSPECTIVE STUDY. 176
Comparative study on ATG-thymoglobulin versus ATG-fresenius for the graft-versus-host disease (GVHD) prophylaxis in allogeneic stem cell transplantation from matched unrelated donor: a single-centre experience over the contemporary years 176
Profile of Toll-Like Receptors on Peripheral Blood Cells in Relation to Acute Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation 170
Betaherpesvirus Reactivation and Toll-Like Receptor Expression After Allogeneic Stem Cell Transplantation. 166
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 158
TARGETING HRASV12G EXPRESSION TO THE ZEBRAFISH EARLY HEMOGENIC PROGENITORS INDUCES A MYELOPROLIFERATIVE DISORDER BY REPRESSING THE NOTCH PATHWAY. 157
Clinical Care of Hematological Patients in a Bone Marrow Transplant Unit: Do Human Resources Influence Infection Incidence? 157
Acute graft-versus-host disease and expression of Toll-like receptors on peripheral blood cells after allogeneic stem cell transplantation 156
Central Venous Catheter-Related Bloodstream Infection Caused by Brevibacterium casei in a Hematology Patient 156
A Gene Panel NGS-Based Strategy for Genomic Characterization of Acute Myeloid Leukemias (AMLs) 155
Expression of Toll-Like Receptors on Peripheral Blood Cells After Allogeneic Stem Cell Transplantation: Results of a Prospective Study. 155
Comparative Somatic Mutational Profiling of CD34+ Hematopoietic Precursors (HSC) and Circulating Endothelial Cells (CEC) in Patients with Primary Myelofibrosis (PMF) 154
Intermittent Imatinib (INTERIM) Treatment of Patients with Ph+ Chronic Myeloid Leukemia in Complete Cytogenetic Response: Cytogenetic and Molecular Data At One Year. 149
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. 148
Multidimensional Geriatric Assessment for Elderly Patients (≥60 years) Submitted for Allogeneic Stem Cell Transplantation. a French (Paris) - Italian (Brescia) 10-Years Experience on 228 Patients 147
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 145
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 144
Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia. 143
Molecular and cytogenetic characterization of a new case of t(5;17)(q35;q21) variant acute promyelocytic leukemia 143
MULTI-GENOTYPING OF MINOR HISTOCOMPATIBILITY ANTIGENS (MHAGS) IN ALLOGENEIC STEM CELL TRANSPLANTATION AND THEIR ROLE IN DETERMINING GRAFT VERSUS HOST DISEASE (GVHD) AND GRAFT VERSUS LEUKEMIA (GVL) EFFECT. 142
Development of BCR-ABL1 Transgenic Zebrafish Model Reproducing Chronic Myeloid Leukemia (CML) Like-Disease and Providing a New Insight into CML Mechanisms 142
Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target? 140
PARAMETERS OF PROTEIN METABOLISM AND THYROID FUNCTION AS PREDICTORS OF A SCORING SYSTEM FOR ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE 140
Advances in CMV Management: A Single Center Real-Life Experience 140
Central nervous system angiitis in Hodgkin's disease. 139
Development of a cell culture model based on biocompatible polymeric scaffolds engineered with human Mesenchymal Stromal Cells (MSCs) for cartilage and bone regenerative therapy 139
Targeting oncogene expression to endothelial cells induces proliferation of the myelo-erythroid lineage by repressing the notch pathway. 138
CMV MANAGEMENT WITH SPECIFIC IMMUNOGLOBULINS: A MULTICENTRIC RETROSPECTIVE ANALYSIS ON 92 ALLOTRANSPLANTED PATIENTS 138
High risk-myelodysplastic syndrome following CAR T-cell therapy in a patient with relapsed diffuse large B cell lymphoma: A case report and literature review 137
Assessment of Liver Damage with Transient Hepatic Elastography (FIBROSCAN) in patients with chronic Graft-Versus-Host Disease. 137
First Interim Report of the Italian Multicentric Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) in Elderly Patients (older than 60 years) with Ph+ Chronic Myeloid Leukemia (CML) and MR3.0/ MR4.0 Stable Molecular Response 136
Single Cell Analysis of Circulating Endothelial Cells in Allogeneic Hematopoietic Stem Cell Transplant; To Whom Do They Belong: Host or Donor? 136
Chitosan-Hydrogel Polymeric Scaffold Acts as an Independent Primary Inducer of Osteogenic Differentiation in Human Mesenchymal Stromal Cells 136
5-azacitidine five days/monthly schedule in symptomatic low-risk (IPSS: 0-1) myelodisplastic (MDS) patients. clinical and biological effects. 135
Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment 135
Second chronic phase before transplantation is crucial for improving survival of blastic phase chronic myeloid leukaemia. 131
Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives 131
Biological versus Clinical Risk Factors in Acute Myeloid Leukemia: Is There a Winner? 131
RT-qPCR versus Digital PCR: How Do They Impact Differently on Clinical Management of Chronic Myeloid Leukemia Patients? 130
Parameters of Protein Metabolism and Thyroid Function As Predictors in a Scoring System for Acute and Chronic Graft-Versus-Host Disease 129
Identification of a Novel Mutation Predisposing to Familial AML and MDS Syndrome By a NGS Approach 129
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. 128
Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-kit positive acute myeloid leukemia. Results of an italian multicentric phase II study. 128
Platelet activation as a novel mechanism of atherothrombotic risk in chronic obstructive pulmonary disease. 128
Advances in the treatment of monoclonal gammapathies: the emerging role of targeted therapy in plasma cell dyscrasias. 127
Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing 127
Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia 125
Index of Bone Marrow Output and Imbalance of B-Lymphocyte Homeostasis before and after Transplantation Correlate Differently with Graft-Versus-Host Disease and Relapse 125
Prompt resolution of nasal aspergillosis with intranasal instillation of liposomal amphotericin-B (amBisome) and granulocyte transfusions 123
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases 123
Parameters of Protein Metabolism and Thyroid Function As Predictors in a Scoring System for Acute and Chronic Graft-Versus-Host Disease 123
CT-290: Clinical Frailty Scale as a Novel Tool to Evaluate Patients’ Eligibility for Allogeneic Stem Cell Transplant: A Single-Center Experience on 234 Patients >50 Years Old 123
Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients. 122
Expression of Toll-like receptors on peripheral blood cells after allogeneic stem cell transplantation: ongoing results of a prospective study. 122
Peripheral Blood WT1 Expression Predicts Relapse in AML Patients Undergoing Allogeneic Stem Cell Transplantation. 122
Ethical and legal issues in haematopoietic stem cells (HSC) donation: the controversial and problematic aspects in minors 121
The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia – analysis of 848 patients. 120
Low dose AraC for Myelodysplastic Syndromes: is it still a current therapy ?. 120
ETV6: A Candidate Gene for Predisposition to “Blend Pedigrees”? A Case Report from the NEXT-Famly Clinical Trial 120
Comparative Study on Fresenius-ATG Versus Thymoglobuline-ATG for the Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Stem Cell Transplantation from Matched Unrelated Donor: A Single Center Experience on 76 Patients 120
ANTI-CMV Immunoglobulins in Association with ANTI-CMV Drugs in Patients with Hematological Malignancies Submitted to Allogeneic STEM CELL Transplantation: A MULTI-Center Retrospective Experience 120
Acute myeloid leukemia in the elderly: results obtained with conventional chemotherapy 119
Urinary Protein Levels in Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) Predict Severe Disease Related Complications at Myeloma Progression 119
Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years 118
Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin. 118
A NEW PROMISING APPROACH TO PERFORM HLA TYPING IN A QUICKLY, SIMPLE AND ACCURATE WAY: THE PYROSEQUENCING 117
AIDA: The italian way of treating acute promyelocytic leukemia (APL): final act . 117
Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia 116
Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study. 116
Liposomal daunorubicin (DAUNOXOME) for treatment of relapsed meningeal acute myeloid leukemia. 116
Conditioning regimens in acute myeloid leukemia. 116
Consolidation therapy for adult acute myeloid leukemia: A systematic analysis according to evidence based medicine 115
Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation. 115
The role of allogeneic hematopoietic stem cell transplantation in the four P medicine era 115
Treatment of Chronic Myeloid Leukemia elderly patients in the Tyrosine Kinase Inhibitor era. 115
Sequential monitoring of lymphocyte subsets and of T-and-B cell neogenesis indexes to identify time-varying immunologic profiles in relation to graft-versus-host disease and relapse after allogeneic stem cell transplantation 115
Four Drugs combination (Fludarabine, Cytarabine, Idarubicin, Etoposide) as induction therapy for newly diagnosed acute myeloid leukemia patients younger than 65 yrs: response and follow up of 127 patients. 115
Expression of Toll-like receptors and Bteherpesvirus reactivation in the early period after allogeneic stem cell transplantation 114
WT1 Monitoring of Minimal Residual Disease (MRD) in Patients with Acute Myeloid Leukemia. 114
PYROSEQUENCING IS A NEW PROMISING APPROACH TO PERFORM HLA TYPING IN A QUICKLY, SIMPLE AND ACCURATE WAY. 114
Brentuximab vedotin in patients with hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four italian centers 114
Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia 113
Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients 113
Changes in Circulating Endothelial Cells Count Could Become a Valuable Tool in the Diagnostic Definition of Acute Graft-Versus-Host Disease. 113
Multidimensional geriatric assessment for elderly hematological patients (≥60 years) submitted to allogeneic stem cell transplantation. A French-Italian 10-year experience on 228 patients 113
Liposomal daunorubicin (DaunoXome) for the treatment of relapsed meningeal acute myeloid leukemia. 112
Genome-Wide Analysis by High-Resolution SNP Array Identifies Novel Genomic Alterations in Acute Promyelocytic Leukemia (APL). 112
Achievmento fo full donor chimerism and minimal residual disease clearance with early dasatinib therapy after intra-bone cord blood transplantation for Philadelphia positive acute lymphoblastic leukaemia: a case report 112
Long term outcome of ph+ cml patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era. 112
Totale 14.217
Salva come PNG Salva come JPEG
Categoria #
all - tutte 205.904
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 205.904
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213.259 0 0 0 0 0 626 191 625 621 557 459 180
2021/20222.684 121 460 55 130 111 203 128 194 141 365 203 573
2022/20232.153 435 45 53 175 162 597 7 199 259 30 91 100
2023/20242.723 125 72 190 140 130 457 122 93 758 32 40 564
2024/20256.853 62 79 68 775 775 559 640 200 896 446 1.300 1.053
2025/20269.155 1.265 2.060 1.266 2.309 1.273 982 0 0 0 0 0 0
Totale 40.954